Jefferies Financial Group Inc. purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 55,878 shares of the company’s stock, valued at approximately $1,519,000. Jefferies Financial Group Inc. owned approximately 0.10% of Maze Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also made changes to their positions in MAZE. Sterling Capital Management LLC grew its holdings in shares of Maze Therapeutics by 390.5% in the third quarter. Sterling Capital Management LLC now owns 1,089 shares of the company’s stock valued at $30,000 after purchasing an additional 867 shares in the last quarter. Royal Bank of Canada increased its stake in Maze Therapeutics by 214.1% during the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after buying an additional 1,383 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics during the 2nd quarter worth approximately $48,000. Quantbot Technologies LP acquired a new stake in Maze Therapeutics during the 2nd quarter worth approximately $80,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Maze Therapeutics during the 3rd quarter worth approximately $77,000.
Insider Buying and Selling at Maze Therapeutics
In other news, CMO Harold Bernstein sold 16,141 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $26.36, for a total transaction of $425,476.76. Following the completion of the sale, the chief marketing officer owned 16,141 shares in the company, valued at approximately $425,476.76. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the completion of the transaction, the chief executive officer owned 18,151 shares of the company’s stock, valued at approximately $477,189.79. The trade was a 65.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 176,849 shares of company stock worth $4,741,878 over the last three months. Insiders own 5.30% of the company’s stock.
Analyst Ratings Changes
Several equities analysts have commented on MAZE shares. Wedbush raised their price target on shares of Maze Therapeutics from $48.00 to $49.00 and gave the company an “outperform” rating in a research report on Tuesday, November 10th. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. JPMorgan Chase & Co. cut their price objective on Maze Therapeutics from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 11th. Citigroup assumed coverage on Maze Therapeutics in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Maze Therapeutics in a report on Thursday, September 24th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $65.50.
Get Our Latest Stock Analysis on MAZE
Maze Therapeutics Stock Performance
MAZE opened at $34.33 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.14 and a current ratio of 14.14. Maze Therapeutics, Inc. has a one year low of $21.95 and a one year high of $53.65. The company has a market cap of $1.88 billion, a P/E ratio of -12.95 and a beta of 2.04. The business’s 50-day simple moving average is $28.68 and its 200-day simple moving average is $31.54.
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, equities research analysts expect that Maze Therapeutics, Inc. will post -2.76 EPS for the current fiscal year.
More Maze Therapeutics News
Here’s some of the latest news about MAZE:
- Positive Sentiment: Wedbush analyst commentary pointed to potential upside in MAZE shares. Maze Therapeutics stock price expected to rise, Wedbush analyst says
- Positive Sentiment: HC Wainwright maintained its Buy rating and $110 price target, despite cutting its forecasts. Maze Therapeutics analyst estimates
- Negative Sentiment: HC Wainwright lowered EPS estimates across 2026–2030, including FY2027 to a loss of $3.15 per share from $2.60 and FY2026 to a loss of $2.86 from $2.63. It also cut estimates for each quarter from Q4 2026 through Q4 2027. The broad revisions signal expectations of larger losses and could pressure the stock. Maze Therapeutics analyst estimates
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.
Recommended Stories
- Five stocks we like better than Maze Therapeutics
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
